GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DNA Group (TR) Ltd (XTAE:DNA) » Definitions » Peter Lynch Fair Value

DNA Group (TR) (XTAE:DNA) Peter Lynch Fair Value : ₪0.05 (As of Jul. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is DNA Group (TR) Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, DNA Group (TR)'s PEG is 1. DNA Group (TR)'s 5-Year TTM EBITDA Growth Rate is 25. DNA Group (TR)'s EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00. Therefore, the Peter Lynch Fair Value for today is ₪0.05.

As of today (2024-07-13), DNA Group (TR)'s share price is ₪0.687. DNA Group (TR)'s Peter Lynch fair value is ₪0.05. Therefore, DNA Group (TR)'s Price to Peter Lynch Fair Value Ratio for today is 13.74.


The historical rank and industry rank for DNA Group (TR)'s Peter Lynch Fair Value or its related term are showing as below:

XTAE:DNA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.32   Med: 6.48   Max: 14.66
Current: 13.74


During the past 11 years, the highest Price to Peter Lynch Fair Value Ratio of DNA Group (TR) was 14.66. The lowest was 0.32. And the median was 6.48.


XTAE:DNA's Price-to-Peter-Lynch-Fair-Value is ranked worse than
97.67% of 86 companies
in the Biotechnology industry
Industry Median: 1.62 vs XTAE:DNA: 13.74

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


DNA Group (TR) Peter Lynch Fair Value Historical Data

The historical data trend for DNA Group (TR)'s Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DNA Group (TR) Peter Lynch Fair Value Chart

DNA Group (TR) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 4.93 - 0.05

DNA Group (TR) Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.93 - - - 0.05

Competitive Comparison of DNA Group (TR)'s Peter Lynch Fair Value

For the Biotechnology subindustry, DNA Group (TR)'s Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DNA Group (TR)'s Price-to-Peter-Lynch-Fair-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DNA Group (TR)'s Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where DNA Group (TR)'s Price-to-Peter-Lynch-Fair-Value falls into.



DNA Group (TR) Peter Lynch Fair Value Calculation

DNA Group (TR)'s Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 25 *0.002
=0.05

For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. DNA Group (TR)'s EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


DNA Group (TR)  (XTAE:DNA) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.

DNA Group (TR)'s Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.687/0.05
=13.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DNA Group (TR) Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of DNA Group (TR)'s Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


DNA Group (TR) (XTAE:DNA) Business Description

Traded in Other Exchanges
N/A
Address
Shimon Hatirsi Street 43, Tel Aviv, ISR, 62492
Website
DNA Group (TR) Ltd invests in biomed companies and has also started to engage in profitable real estate in England.